SCHEMBL15345121

SCHEMBL15345121

Cc1ccnc(-c2ccc3c(c2)c(C)nn3C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.47
ADORA2B P29275 1/20 0.47
CCR1 P32246 1/20 0.47
CCR5 P51681 1/20 0.47
CCR8 P51685 1/20 0.47
CYP2A6 P11509 1/20 0.43
GRM4 Q14833 1/20 0.39
BRD4 O60885 2/20 0.38
CREBBP Q92793 1/20 0.38
SLC2A1 P11166 1/20 0.38
METAP2 P50579 1/20 0.36
LSS P48449 1/20 0.36
UHRF1 Q96T88 1/20 0.35
CNR1 P21554 1/20 0.34
MCHR1 Q99705 1/20 0.34
CLK1 P49759 1/20 0.34
DYRK1A Q13627 1/20 0.34
ABL1 P00519 1/20 0.34
BCR P11274 1/20 0.34
NAMPT P43490 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15344984 0.85 SLC2A1 (0.51) CCR1CCR5CCR8CYP2A6SLC2A1
SCHEMBL15341924 0.85 ADORA2A (0.41) ADORA2AADORA2BCCR1CCR5CCR8
SCHEMBL15344112 0.81 CREBBP (0.44) CCR1CCR5CCR8CYP2A6GRM4
SCHEMBL15344958 0.80 CCR1 (0.53) ADORA2AADORA2BCCR1CCR5CCR8
SCHEMBL29769107 0.78 ADORA2A (0.63) ADORA2AADORA2BGRM4BRD4CREBBP
SCHEMBL5985731 0.78 ADORA2A (0.63) ADORA2AADORA2BGRM4BRD4CREBBP
SCHEMBL15344957 0.77 CCR1 (0.44) ADORA2AADORA2BCCR1CCR5CCR8
SCHEMBL15345193 0.76 TDO2 (0.49) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL15345002 0.75 CCR1 (0.46) CCR1CCR5CCR8CYP2A6METAP2
SCHEMBL31695263 0.74 CCR1 (0.76) CCR1CCR5CCR8CYP2A6METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 ADORA2A 1666/4885ADORA2B 2421/4885CCR1 106/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 ADORA2A 1666/4885ADORA2B 2421/4885CCR1 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.